Asset Details
Do you wish to reserve the book?
Rapid agitation control with ketamine in the emergency department (RACKED): a randomized controlled trial protocol
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Rapid agitation control with ketamine in the emergency department (RACKED): a randomized controlled trial protocol
Do you wish to request the book?
Rapid agitation control with ketamine in the emergency department (RACKED): a randomized controlled trial protocol
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Rapid agitation control with ketamine in the emergency department (RACKED): a randomized controlled trial protocol
2018
Overview
Background
The rapid control of patients presenting to the emergency department (ED) with psychomotor agitation and violent behavior is paramount for the safety of patients and ED staff. The use of intramuscular (IM) ketamine in the pre-hospital and ED settings has demonstrated promising preliminary results to provide rapid and safe behavioral control. A prospective, randomized controlled trial is required to measure the potential superiority of IM ketamine compared to current standard care (IM benzodiazepines plus antipsychotics).
Methods
This will be a parallel, prospective, randomized, controlled trial of 5 mg/kg IM ketamine compared to a combination of 5 mg IM midazolam and 5 mg IM haloperidol. The study will enroll approximately 184 patients, randomized equally to two study arms. There will be one study visit during which study medication will be administered and assessments will be completed. A follow-up safety visit will occur on day 3. The primary objective of this study is to compare IM ketamine to a combination of IM midazolam and haloperidol with regards to the time required for adequate behavioral control, in minutes, in patients presenting to the ED with psychomotor agitation and violent behavior, as measured by the Richmond Agitation-Sedation Scale (RASS).
Discussion
We present a novel study to determine whether ketamine is a rapid and safe option, compared to a combination of midazolam and haloperidol for the sedation of patients presenting to the ED with psychomotor agitation and violent behavior. To our knowledge, this study is the first randomized controlled trial to compare ketamine to current standard care for this indication. We have attempted to address numerous logistical issues with the design of this study including a waiver of consent, ensuring adequate blinding of outcome assessors, patient enrolment, and data monitoring.
Trial registration
Clinicaltrials.gov,
NCT03375671
. Registered on 18 December 2017.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Anesthetics, Dissociative - administration & dosage
/ Anesthetics, Dissociative - adverse effects
/ Behavior
/ Consent
/ Female
/ Haloperidol - administration & dosage
/ Humans
/ Hypnotics and Sedatives - administration & dosage
/ Hypnotics and Sedatives - adverse effects
/ Ketamine
/ Ketamine - administration & dosage
/ Male
/ Medicine
/ Methods
/ Midazolam - administration & dosage
/ Psychomotor Agitation - diagnosis
/ Psychomotor Agitation - drug therapy
/ Psychomotor Agitation - physiopathology
/ Psychomotor Agitation - psychology
/ Randomized Controlled Trials as Topic
/ Statistics for Life Sciences
